United States: Proposal To Overhaul FDA's Over-The-Counter Drug Monograph Process Closer To Reality

Last Updated: December 18 2018
Article by Rebecca L. Dandeker, Ann M. Begley and Kathleen M. Sanzo

A new pathway for over-the-counter (OTC) products could be on the horizon as both houses of Congress proposed bills to revise the US Food and Drug Administration's (FDA's) procedures to allow OTC medications to be marketed, and to permit FDA to collect user fees, potentially expediting a newly created OTC drug review process. FDA is preparing for an eventual passage of the law, and so should OTC drug manufacturers and private label distributors.

The US House of Representatives voted on July 17, 2018, to pass a bill to reform the OTC monograph process entitled the Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018.1 The Senate companion bill cleared the Health, Education, Labor, and Pensions Committee on April 24, 2018, and is pending a floor vote.2 The bills would add new sections to the Federal Food, Drug, and Cosmetic Act (FFDCA) to remove the current notice-and-comment rulemaking procedures governing the market introduction of OTC drugs, and instead institute a different, possibly more efficient, administrative order process. Some political analysts predict that the bills could become law in the near future.

Background

The FDA (or Agency) regulates most OTC drugs under the "OTC Monograph Process," although manufacturers have the option to file a new drug application (NDA) for novel OTC products. The OTC Monograph Process was created by FDA in 1972 to review the safety and efficacy of active ingredients contained in thousands of medicines marketed without a prescription. Rather than having each product approved by the Agency, the monographs established conditions under which active ingredients, combinations of active ingredients, indications, dosage forms, and labeled directions are generally recognized as safe and effective (GRASE) for use.

There are three categories under the OTC Monograph Process: Category I are ingredients that are GRASE and can be marketed without FDA review. Category II are ingredients that are not considered GRASE and cannot be lawfully marketed except through the FDA's NDA approval process. Category III are ingredients for which FDA requires more data to determine whether they are GRASE.

Over the 40-plus-year rulemaking process, FDA enforcement discretion has allowed almost all proposed Category I and Category III ingredients to continue to be marketed in the absence of a safety concern. Under the existing system, once FDA issues a Final Monograph with the final Category I ingredients identified, all Category III ingredients must be removed from the market. Today, this process remains incomplete, with several significant monographs still pending as "tentative" final monographs or TFMs (e.g., sunscreen, antimicrobials, external analgesics).

The current monograph process has been criticized as slow and a barrier to the introduction of new OTC ingredients to the US market. The proposed bills attempt to modernize the process by allowing FDA to make OTC product decisions through an administrative order process that replaces the existing notice-and-comment rulemaking procedures. The bills provide a process for public comments, mandate alternative dispute resolution concerning ingredient decisions, and allow manufacturers to request GRASE determination of new ingredients or new conditions for use through administrative orders, all of which will occur in a much shorter timeframe than the current process. The bills also authorize FDA to move quickly to categorize products as non-GRASE if no data is submitted. Further, the legislation establishes a user fee program to pay for FDA's review based on new ingredient/uses and annual facility registrations. The fees currently proposed for order requests are either $100,000 or $500,000, depending on the complexity of review, and annual facility fees are to be established yearly by FDA to meet statutory fee revenue requirements.

The bills will incorporate the existing Final Monographs and TFMs by reference in the statute and automatically classify any Category I ingredient in a Final Monograph or TFM as GRASE. The proposed bills will continue to allow Category III ingredients presently subject to a TFM, and Category I ingredients subject to an advanced notice of proposed rulemaking (ANPRM), to be marketed without an approved new drug application unless otherwise directed by an administrative order.

Notably, except in the case of a "minor change" or as permitted under an order, these ingredients can be marketed only in a dosage form that has been used to a material extent and for a material time immediately prior to enactment of the proposed bill. However, a "minor change" to a dosage form is allowable where it does not change the safety, effectiveness, or the absorption or exposure to the ingredient. Such a minor change would be allowed without the need to update or amend the order, and the bills direct the FDA to issue necessary administrative orders and guidance to clarify for industry when a "minor change" meets these conditions. Furthermore, the bills adopt a "safety in labeling" clause that allows FDA to quickly make changes to any final order if new evidence becomes available to suggest a particular drug or class of drugs poses an unreasonable risk of an adverse event and requires a label or other change.

The most significant substantive change to the regulatory framework is that both bills allow FDA to grant market exclusivity for either an active ingredient not previously included in a monograph or order, or a new condition for use, so long as new human studies were conducted that were essential to the issuance of a final administrative order. The bill provides no direction on how FDA will assess whether the ingredients or conditions for use are the same as those previously marketed. Moreover, the House and Senate bills diverge on the effective date and length of exclusivities to be granted, which is the only major difference between the two bills. The House bill would allow an 18-month market exclusivity period, while the Senate bill extends the exclusivity to 24 months. The Senate bill also starts the clock on exclusivity when FDA grants a sponsor's request through an administrative order, while the House delays the effective date of the exclusivity period until a sponsor submits an updated drug listing after the issuance of the final order. This latter approach may be closer to the company's actual market launch date.

Key Highlights and Takeaways

  • The Senate and House versions of the bill are largely similar, with the exception of the exclusivity provisions; therefore, manufacturers can reasonably rely on the major provisions of the bill, such as the administrative procedures, application of user fees, and adoption of monographs by reference, to remain the same or similar if the bill is passed into law.

  • Because the regulatory process will be streamlined and FDA will presumably have more resources and staff through the addition of user fees, manufacturers can expect a faster review time for FDA decisions on new active ingredients or dosage forms. However, the OTC review time will not be as swift as the NDA review time of 10–12 months. As indicated in FDA's 2018–2022 OTC Monograph Goals Letter3, the proposed review timeframes are 17.5 months after receipt of an OTC Monograph Order Request for Tier 1 innovations that do not have numerous or substantive public comments, and 23.5 months for Tier 2 requests that garner substantive comments. However, like NDA reviews, these are "expected" average times, and likely will be extended due to submissions deemed by FDA to be deficient.

    Manufacturers can start preparing for the proposed new review system by organizing their current OTC product portfolio according to the ingredients' current monograph classification. Manufacturers should be cognizant of their Category III active ingredients subject to a TFM, Category I ingredients subject to an ANPRM, and Category II drugs. These ingredients are at risk for more immediate FDA action that could quickly impact their regulatory and marketing status.

  • Manufacturers interested in changing a condition for use or an ingredient in a monograph will have the ability to do so by making a request to FDA through an OTC monograph order request, or "OMOR." Minor changes to dosage forms that do not impact safety, effectiveness, absorption, or exposure to the active ingredient would not require a new order, but must meet conditions set forth in relevant FDA administrative orders and guidance.

  • The future OMOR exclusivity period (either 18 months or two years) will apply to OTC monograph products with new active ingredients, combinations of new ingredients, or new conditions for use for which clinical studies were essential to the issuance of the order. It is not clear how different an ingredient or condition for use must be in order to obtain exclusivity.

  • Furthermore, the exclusivity will only block the sale of OTC products that seek to enter the market during the exclusivity period with the new active ingredient(s) or new condition for use.

  • Finally, the legislation is silent, and FDA has not commented, on how the public will be notified of exclusivity periods, or whether some type of certifications of status will be required in the OMORs.

Footnotes

1 Over-the-Counter Monograph Safety, Innovation and Reform Act, HR 5333, 115 Cong. (2018).

2 Over-the-Counter Drug Safety, Innovation, and Reform Act, S 2315, 115 Cong. (2018).

3 Food & Drug Admin., Over-the-Counter Monograph User Free Program Performance Procedures – Fiscal Years 2018-2022.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions